Related Experiment Video
Updated: Oct 23, 2025
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Update: Drug treatment options for coronavirus disease 2019 (COVID-19)
Yueming Shao1, Jun Chen1, Hongzhou Lu1,2
1Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Abstract:
Coronavirus disease 19 (COVID-19) continues to rage as a global pandemic. A number of potential therapeutic agents have been explored over the past year or two. However, numerous drugs that were expected to prove highly effective, such as lopinavir/ritonavir and remdesivir, have been found to have little benefit in large clinical trials. Interleukin-6 receptor antagonists, glucocorticoids, Janus kinase inhibitors, and some antivirals have been found to provide significant benefits in terms of reducing viral load, reducing the time of nucleic acid conversion, or improving survival. For example, bamlanivimab and etesevimab, which are newly designed monoclonal antibodies against the surface spike protein S1 subunit receptor-binding domain (RBD) of SARS-CoV-2, have a significant effect on reducing the viral load and the hospitalization rate of patients with mild COVID-19. Several vaccines against SARS-CoV-2 have been widely administered worldwide and have provided good protection. Nevertheless, the increasingly hardy variants of the virus have raised the requirements for vaccine design. Perhaps RBD-based vaccines are a viable way to defend against variants, but this still needs to be verified in a large sample. Therefore, this paper provides an update on the treatment options for COVID-19 based on three previously proposed dimensions of drug screening: standard assays of existing broad-spectrum antivirals, screening of chemical libraries, and redevelopment of new, specific drugs.
Insights
Effective COVID-19 treatments include certain antivirals, monoclonal antibodies like bamlanivimab, and receptor antagonists. Research continues for new therapies and vaccines against evolving SARS-CoV-2 variants.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- The COVID-19 pandemic necessitates ongoing research into effective therapeutic agents.
- Many initially promising drugs, such as lopinavir/ritonavir and remdesivir, showed limited efficacy in large clinical trials.
- Emerging SARS-CoV-2 variants pose challenges to existing vaccines and treatments.
Purpose of the Study:
- To provide an updated review of COVID-19 treatment options.
- To evaluate therapeutic strategies based on drug screening dimensions: existing antivirals, chemical libraries, and novel drug development.
- To discuss the potential of receptor-binding domain (RBD)-based vaccines against viral variants.
Main Methods:
- Review of clinical trial data for various therapeutic agents.
- Analysis of drug screening methodologies for antiviral development.
- Assessment of monoclonal antibodies targeting SARS-CoV-2 spike protein.
- Evaluation of vaccine efficacy and design considerations for variants.
Main Results:
- Interleukin-6 receptor antagonists, glucocorticoids, Janus kinase inhibitors, and some antivirals demonstrate significant benefits.
- Monoclonal antibodies bamlanivimab and etesevimab effectively reduce viral load and hospitalization rates in mild COVID-19.
- Current vaccines offer protection but require adaptation for increasingly resistant SARS-CoV-2 variants.
- RBD-based vaccines show promise but require further large-scale validation.
Conclusions:
- Several drug classes and specific agents offer significant therapeutic benefits for COVID-19.
- Monoclonal antibodies are effective for mild cases, reducing viral load and hospitalizations.
- Vaccine development must address evolving SARS-CoV-2 variants, with RBD-based approaches being a potential strategy.
- Continued drug screening and development are crucial for managing the pandemic.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:27Coronary Artery Disease V: Interprofessional Care
01:22Alzheimer's Disease: Treatment